Company / Operating Income
Silo Pharma, Inc. Operating Income History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$4.7M
FY2025
5-year range
-$4.7M / -$594.2K
FY2021-FY2025
Trend
-22.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has declined for 4 consecutive years, from -$594,242 in FY2019 to -$5M in FY2025.
Based on SEC 10-K filings.
-$5M in FY2025.
Declined from -$4M to -$5M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Silo Pharma, Inc.'s operating income has declined for 4 consecutive years.
- In FY2025, operating income decreased 22.0% year-over-year.
- Peak operating income was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.7M | -22.0% |
| FY2024 | -$3.9M | -6.3% |
| FY2023 | -$3.6M | -289.9% |
| FY2020 | -$930.4K | -56.6% |
| FY2019 | -$594.2K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026